Price T Rowe Associates Inc Exelixis, Inc. Transaction History

Price T Rowe Associates Inc

  • $867 Billion
  • Q4 2024

A detailed history of Price T Rowe Associates Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,766,841 shares of EXEL stock, worth $65.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,766,841
Previous 1,891,847 6.61%
Holding current value
$65.3 Million
Previous $49.1 Million 19.85%
% of portfolio
0.01%
Previous 0.01%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
SELL
$25.39 - $36.46 $3.17 Million - $4.56 Million
-125,006 Reduced 6.61%
1,766,841 $58.8 Million
Q3 2024

Nov 14, 2024
SELL
$21.96 - $27.6 $1.27 Million - $1.6 Million
-58,021 Reduced 2.98%
1,891,847 $49.1 Million
Q2 2024

Aug 14, 2024
SELL
$20.34 - $23.73 $28.2 Million - $32.9 Million
-1,388,370 Reduced 41.59%
1,949,868 $43.8 Million
Q1 2024

May 15, 2024
SELL
$20.17 - $23.93 $6.28 Million - $7.45 Million
-311,435 Reduced 8.53%
3,338,238 $79.2 Million
Q4 2023

Feb 14, 2024
SELL
$19.25 - $24.13 $15.8 Million - $19.9 Million
-823,151 Reduced 18.4%
3,649,673 $87.6 Million
Q3 2023

Nov 14, 2023
SELL
$19.04 - $22.74 $9.06 Million - $10.8 Million
-475,990 Reduced 9.62%
4,472,824 $97.7 Million
Q2 2023

Aug 14, 2023
SELL
$18.17 - $20.48 $19.3 Million - $21.8 Million
-1,063,974 Reduced 17.7%
4,948,814 $94.6 Million
Q1 2023

May 15, 2023
SELL
$16.3 - $19.41 $10 Million - $11.9 Million
-615,102 Reduced 9.28%
6,012,788 $117 Million
Q4 2022

Feb 14, 2023
SELL
$14.96 - $17.39 $20.9 Million - $24.3 Million
-1,395,152 Reduced 17.39%
6,627,890 $106 Million
Q3 2022

Nov 14, 2022
SELL
$15.68 - $22.27 $84.7 Million - $120 Million
-5,401,973 Reduced 40.24%
8,023,042 $126 Million
Q2 2022

Aug 15, 2022
SELL
$17.44 - $23.16 $41 Million - $54.4 Million
-2,348,770 Reduced 14.89%
13,425,015 $280 Million
Q1 2022

May 16, 2022
SELL
$17.03 - $22.67 $22.6 Million - $30.1 Million
-1,326,182 Reduced 7.76%
15,773,785 $358 Million
Q4 2021

Feb 14, 2022
SELL
$15.84 - $21.88 $2.17 Million - $3 Million
-137,168 Reduced 0.8%
17,099,967 $313 Million
Q3 2021

Nov 15, 2021
SELL
$16.3 - $21.14 $39.7 Million - $51.5 Million
-2,438,405 Reduced 12.39%
17,237,135 $364 Million
Q2 2021

Aug 16, 2021
SELL
$17.95 - $25.56 $19 Million - $27.1 Million
-1,058,798 Reduced 5.11%
19,675,540 $358 Million
Q1 2021

May 17, 2021
BUY
$20.53 - $25.22 $64.6 Million - $79.3 Million
3,145,844 Added 17.89%
20,734,338 $468 Million
Q4 2020

Feb 16, 2021
BUY
$18.39 - $24.8 $323 Million - $436 Million
17,588,494 New
17,588,494 $353 Million

Others Institutions Holding EXEL

# of Institutions
566
Shares Held
251M
Call Options Held
1.45M
Put Options Held
1.13M
View Full List

About EXELIXIS, INC.

EXEL Quotes by TradingView
  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.9B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email